Caribou Biosciences, Inc.
https://cariboubio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Caribou Biosciences, Inc.
Deal Watch: AbbVie Adds To Immunology Pipeline Through Deal With OSE
Plus deals involving Novo Nordisk/Neomorph, Mabwell/Jiangsu Haibo, Alteogen/Merck & Co., Gilead/Biocytogen, AlphaGen/ARTBIO and XOMA/Kinnate.
Unpartnered Assets To Watch In 2024
Licensing serves as a strategic R&D avenue for major developers amid a shrinking M&A market. In Vivo has detected five high-value unpartnered assets that might be the focus of dealmaking activity in the coming months.
Sana Lifted By Allo-CAR-T Data, Moves Ahead Into Autoimmune Disease
Sana claims to has cracked one of allo-CAR-Ts biggest challenges, blocking NK cells from destroying the therapies, and for now, investors are impressed.
AbbVie Looks To Umoja To Partner On In Vivo CAR-Ts
Umoja’s technology is meant to enable development of CAR-Ts that could potentially overcome the challenges associated with autologous cell therapies, especially related to manufacturing.
Company Information
- Industry
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
-
Drug Discovery Tools
- Genomics-Proteomics
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice